“Erlotinib As Second-Line Therapy for Patients With Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors”. Journal of Analytical Oncology 4, no. 3 (June 20, 2015):  94–101. Accessed April 15, 2026. https://neoplasiaresearch.com/index.php/jao/article/view/250.